-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Karyopharm Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2023.
- Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $28K, a 133% increase year-over-year.
- Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $296K, a 11.3% increase year-over-year.
- Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $323K, a 12.5% decline from 2022.
- Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $369K, a 37.7% increase from 2021.
- Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2021 was $268K, a 13.3% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)